GH Research (NASDAQ:GHRS) Stock Price Up 2.2% – Here’s Why

Shares of GH Research PLC (NASDAQ:GHRS) shot up 2.2% on Friday . The company traded as high as $8.76 and last traded at $8.28. 36,299 shares were traded during mid-day trading, a decline of 54% from the average session volume of 79,613 shares. The stock had previously closed at $8.10.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GHRS shares. JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th.

GH Research Trading Up 0.6 %

The business has a 50-day simple moving average of $8.02 and a two-hundred day simple moving average of $10.52.

GH Research (NASDAQ:GHRS) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Equities analysts forecast that GH Research PLC will post -0.85 EPS for the current year.

Institutional Investors Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. lifted its position in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the period. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).